NCT00290914已完成2 期
Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder
Pharmacology Research Institute0 个研究点开始时间: 2006年2月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients 18-65 years of age, inclusive.
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive DisorderMajor Depressive DisorderNCT01878292Forest Laboratories529
已完成
3 期
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety DisorderGeneralized Anxiety DisorderNCT01844115Forest Laboratories415
已完成
3 期
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety DisorderGeneralized Anxiety DisorderNCT01766401Forest Laboratories402
已完成
3 期
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety DisorderGeneralized Anxiety DisorderNCT01629966Forest Laboratories680
已完成
3 期
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)Major Depressive DisorderNCT02372799Forest Laboratories473